eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
1/2023
vol. 25
 
Share:
Send email
Share:
Review paper

Adult pneumococcal vaccination – new opportunities

Ernest Kuchar
1
,
Joanna Chorostowska-Wynimko
2
,
Leszek Czupryniak
3
,
Andrzej Fal
4, 5
,
Robert Flisiak
6
,
Artur Mamcarz
7
,
Aneta Nitsch-Osuch
8
,
Anna Skoczyńska
9
,
Marcin Stajszczyk
10
,
Jacek Wysocki
11
,
Michał Abendort
12
,
Dominik Golicki
13
,
Katarzyna Jaśkowiak
14
,
Adam Antczak
15

  1. Department of Paediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, Poland
  2. Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
  3. Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
  4. Department of Allergology, Lung Diseases and Internal Diseases, Central Clinical Hospital of the Ministry of Interior and Admin-istration, Warsaw, Poland
  5. Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland
  6. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland
  7. 3rd Department of Internal Diseases and Cardiology, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland
  8. Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland
  9. National Reference Centre for Bacterial Meningitis (KOROUN), Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland
  10. Department of Rheumatology and Autoimmune Diseases, Silesian Centre for Rheumatology, Orthopaedics and Rehabilitation, Ustron, Poland
  11. Chair and Department of Health Prevention, Faculty of Health Sciences Poznan University of Medical Sciences, Poznan, Poland
  12. Pfizer Polska Sp. z o.o., Warsaw, Poland
  13. Chair and Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
  14. HealthQuest Sp. z o.o., Warsaw, Poland
  15. Department of General and Oncological Pulmonology, Medical University of Lodz, Lodz, Poland
Family Medicine & Primary Care Review 2023; 25(1): 93–101
DOI: https://doi.org/10.5114/fmpcr.2023.125500
Online publish date: 2023/03/31
Article file
- 16 FM&PCR 1 23 - R - Kuchar - Adult Pneumococcal - 1271.pdf  [0.51 MB]
Get citation
 
PlumX metrics:
 
1. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia (Nathan) 2020; 12: 11.
2. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67(1): 71–79.
3. European Centre for Diseases Prevention and Control. Surveillance Atlas of Infectious Diseases: invasive pneumococcal diseases in 2020 [cited 24.05.2022]. Available from URL: https://atlas.ecdc.europa.eu/public/index.aspx.
4. Pallotta A, Rehm SJ. Navigating pneumococcal vaccination in adults. Cleve Clin J Med 2016; 83(6): 427–433.
5. Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diag-nostic techniques. PLoS ONE 2013; 8(4): e60273.
6. Brandenburg JA, Marrie TJ, Coley CM, et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med 2000; 15(9): 638–646.
7. Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses 2016; 10(5): 394–403.
8. European Respiratory Society. European Lung White Book. Chapter 18: Acute lower respiratory infections [cited 09.06.2022]. Available from URL: https://www.erswhitebook.org/.
9. Jaśkowiak K, Dudzisz A, Golicki D. Zapalenia płuc u osób dorosłych w Polsce – pneumokokowe zapalenia płuc i ich profilaktyka. Lekarz POZ 2021; 7: 2 (in Polish).
10. Hryniewicz W, Albrecht P, Radzikowski A. (red.). Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego. Warszawa: Narodowy Instytut Leków; 2017 [cited 24.05.2022]. Available from URL: http://antybiotyki.edu.pl/wp-content/uploads/Rekomendacje/Rekomendacje2016.pdf (in Polish).
11. Wyrwich KW, Yu H, Sato R, et al. Observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia report-ed by older adults surveyed nationwide using the CAP. Burden of Illness Questionnaire. Patient Relat Outcome Meas 2015: 6: 215–223.
12. Ruiz LA, Serrano L, España PP, et al. Factors influencing long-term survival after hospitalization with pneumococcal pneumonia. J Infect 2019; 79(6): 542–549.
13. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014; 1(1): ofu024.
14. Krone CL, Groep K van de, Trzciński K, et al. Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions. Lancet Respir Med 2014; 2(2): 141–153.
15. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009; 22(11): 1041–1050.
16. Steens A, Vestrheim DF, Aaberge IS, et al. A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older. Epidemiol Infect 2014; 142(12): 2471–2482.
17. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71(4): 109–117.
18. Greene CM, Kyaw MH, Ray SM, et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001–2003. Clin Infect Dis 2006; 43(2): 141–150.
19. Centers for Disease Control and Prevention. Prevention of pneumococcal infections secondary to seasonal and 2009 H1N1 influenza viruses infec-tion [cited 06.06.2022]. Available from URL: http://www.cdc.gov/h1n1flu/vaccination/provider/provider_pneumococcal.htm.
20. Kupronis BA, Richards CL, Whitney CG. Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003; 51(11): 1520–1525.
21. Hoek AJ van, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65(1): 17–24.
22. Centers for Disease Control and Prevention. CDC Yellow Book 2020. Immunocompromised Travelers [cited 17.06.2022]. Available from URL: https://wwwnc.cdc.gov/travel/yellowbook/2020/travelers-with-additional-considerations/immunocompromised-travelers.
23. [Summary of Product Characteristics Pneumovax23®] [cited 19.12.2022]. Available from URL: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/21888/characteristic (in Polish).
24. [Summary of Product Characteristics Prevenar13®] [cited 19.12.2022]. Available from URL: ema.europa.eu/en/documents/product-information/prevenar-13-epar-product-information_pl.pdf (in Polish).
25. [Summary of Product Characteristics Apexxnar®] [cited 19.12.2022]. Available from URL: https://www.ema.europa.eu/en/documents/product-information/apexxnar-epar-product-information_pl.pdf (in Polish).
26. [Summary of Product Characteristics Vaxneuvance®] [cited: 19.12.2022]: Available from URL: https://www.ema.europa.eu/en/documents/product-information/vaxneuvance-epar-product-information_pl.pdf (in Polish).
27. Matanock A, Lee G, Gierke R, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥ 65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68(46): 1069–1075. Erratum in: MMWR Morb Mortal Wkly Rep 2020; 68(5152): 1195.
28. Centers for Disease Control and Prevention. Types and Composition of Pneumococcal Vaccines [cited 24.05.2022]. Available from URL: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/about-vaccine.html.
29. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 2013(1): CD000422.
30. Niederman MS, Folaranmi T, Buchwald UK, et al. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumo-coccal disease and related outcomes: a review of available evidence. Expert Rev Vaccines 2021; 20(3): 243–256.
31. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9(3): 213–220.
32. Schmoele-Thoma B, Jackson LA, Greenberg RN, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions. J Vaccines Immun 2015, 3(2): 7–12.
33. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372(12): 1114–1125.
34. Werkhoven CH van, Huijts SM, Bolkenbaas M, et al. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin Infect Dis 2015; 61(12): 1835–1838.
35. Centers for Disease Control and Prevention. Pneumococcal Disease, Surveillance & Reporting [cited 24.05.2022]. Available from URL: https://www.cdc.gov/pneumococcal/surveillance.html.
36. Desai AP, Sharma D, Crispell EK, et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneu-mococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J 2015; 34(11): 1168–1174.
37. Deursen AMM van, Houten MA van, Webber C, et al. The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Com-munity Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study. Clin Infect Dis 2018; 67(1): 42–49.
38. Herva E, Luotenen J, Timonen M, et al. The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of streptococcus pneumoniae. Scand J Inf Dis 1980; 12(2): 97–100.
39. European Medicines Agency. Summary of positive opinion for Prevenar 13. London, 2009 [cited 08.06.2022]. Available from URL: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-prevenar-13_en.pdf.
40. Suaya JA, Jiang Q, Scott DA, et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine 2018; 36(11): 1477–1483.
41. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-Valent Pneumo-coccal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin Infect Dis 2018; 67(10): 1498–1506.
42. Love BL, Finney CJ, Gaidos JKJ. Effectiveness of Conjugate and Polysaccharide Pneumococcal Vaccines for Prevention of Severe Pneumococcal Disease Among Inflammatory Bowel Disease Patients. J Crohns Colitis 2021; 15(8): 1279–1283.
43. Andrews N, Kent A, Amin-Chowdhury Z, et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006–2018. Vaccine 2019; 37(32): 4491–4498.
44. Hanquet G, Krizova P, Dalby T, et al. Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Coun-tries, Europe. Emerg Infect Dis 2022; 28(1): 137–138.
45. European Centre for Diseases Prevention and Control. Annual epidemiological report for 2018. Stockholm: ECDC; 2020 [cited 24.05.2022]. Available from URL: https://www.ecdc.europa.eu/en/publications-data/invasive-pneumococcal-disease-annual-epidemiological-report-2018.
46. Skoczyńska A, Wróbel-Pawelczyk I, Gołębiewska A, et al. Inwazyjna choroba pneumokokowa w Polsce w 2021 roku (dane KOROUN) [cited 26.05.2022]. Available from URL: http://koroun.nil.gov.pl/dane-epidemiologiczne/ (in Polish).
47. Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS ONE 2017; 12(5): e0177113.
48. Metcalf BJ, Gertz RE Jr, Gladstone RA, et al. Active Bacterial Core surveillance team. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect 2016; 22(1): 60.e9–60.e29.
49. Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease with the 13-Valent Pneumococcal Conju-gate Vaccine. Clin Infect Dis 2016; 62(9): 1119–1125.
50. Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children. Clin Infect Dis 2015; 61(5): 767–775.
51. Oligbu G, Collins S, Sheppard CL, et al. Childhood Deaths Attributable to Invasive Pneumococcal Disease in England and Wales, 2006–2014. Clin Infect Dis 2017; 65(2): 308–314.
52. Zivich PN, Grabenstein JD, Becker-Dreps SI, et al. Streptococcus pneumoniae outbreaks and implications for transmission and control: a systematic review. Pneumonia (Nathan) 2018; 10: 11.
53. Essink B, Sabharwal C, Cannon K, et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults 18 Years and Older. Clin Infect Dis 2021: ciab990.
54. Cannon K, Elder C, Young M, et al. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥ 65 years of age with different prior pneumococcal vaccination. Vaccine 2021; 39(51): 7494–7502.
55. Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumo-coccal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine 2021; 39(38): 5428–5435.
56. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report. Apexxnar. EMA/12384/2022 [cited 08.06.2022]. Available from URL: https://www.ema.europa.eu/en/documents/assessment-report/apexxnar-epar-public-assessment-report_en.pdf.
57. Stoecker C. Advisory Committee on Immunization Practices (ACIP) Meeting, June 2021 [cited 08.06.2022]. Available from URL: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-Pneumococcal-Stoecker-508.pdf.
58. Leidner AJ. Advisory Committee on Immunization Practices (ACIP) Meeting, September 2021 [cited 08.06.2022]. Available from URL: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-09-29/02-Pneumococcal-Leidner-508.pdf.
59. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheu-matic diseases. Ann Rheum Dis 2020; 79(1): 39–52.
60. Główny Inspektorat Sanitarny. Program Szczepień Ochronnych na rok 2022 [cited 08.06.2022]. Available from URL: https://www.gov.pl/web/gis/program-szczepien-ochronnych-na-rok-2022 (in Polish).
61. Komunikat Głównego Inspektora Sanitarnego z dnia 29 października 2012 r. w sprawie Programu Szczepień Ochronnych na rok 2013. Dz.Urz.MZ.2012.78 [cited 08.09.2022]. Available from URL: https://sip.lex.pl/akty-prawne/dzienniki-resortowe/program-szczepien-ochronnych-na-rok-2013-34697535 (in Polish).
62. Obwieszczenie Ministra Zdrowia z dnia 20 grudnia 2021 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia ży-wieniowego oraz wyrobów medycznych na 1 stycznia 2022 r. [cited 08.06.2022]. Available from URL: https://www.gov.pl/web/zdrowie/obwieszczenia-ministra-zdrowia-lista-lekow-refundowanych (in Polish).
63. Agencja Oceny Technologii Medycznych i Taryfikacji. Biuletyn informacji publicznej. Opinie do programów polityki zdrowotnej [cited 08.06.2022]. Availa-ble from URL: https://bipold.aotm.gov.pl/index.php/repozytorium-ppz-2/opinie-o-projektach-programow-zdrowotnych-realizowanych-przez-jst (in Polish).
64. Ministerstwo Zdrowia. Komunikat w sprawie wykonywania szczepień ochronnych w czasie pandemii COVID-19 [cited 09.06.2022]. Available from URL: https://www.gov.pl/web/zdrowie/komunikat-sprawie-wykonywania-szczepien-ochronnych-w-czasie-pandemii-covid-19 (in Polish).
65. World Health Organization. Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region [cited 09.06.2022]. Avail-able from URL: https://apps.who.int/iris/handle/10665/334123.
66. Zorginstituut Nederland [cited 09.06.2022]. Available from URL: https://www.zorginstituutnederland.nl/publicaties/adviezen/2021/03/03/gvs-advies-13-valent-pneumokokkenconjugaat-vaccin-prevenar13.
67. Junta de Andalucia [cited 09.06.2022]. Available from URL: https://www.juntadeandalucia.es/export/drupaljda/instruccion_vacunacion_neumococica_pacientes_post_covid_grave_26-11-2020-F.pdf .
Copyright: © 2023 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.